<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <previousAccessionNumber>0001564590-22-023327</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Griffiths Richard Ian -->
          <cik>0001846370</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>11</amendmentNo>
      <securitiesClassTitle>Ordinary Shares, nominal value of PS0.05 per share</securitiesClassTitle>
      <dateOfEvent>08/12/2026</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001479615</issuerCIK>
        <issuerCusips>
          <issuerCusipNumber>G8128Y157</issuerCusipNumber>
        </issuerCusips>
        <issuerName>Silence Therapeutics Plc</issuerName>
        <address>
          <com:street1>72 Hammersmith Road</com:street1>
          <com:city>London</com:city>
          <com:stateOrCountry>X0</com:stateOrCountry>
          <com:zipCode>W14 8TH</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Richard Griffiths</personName>
          <personPhoneNum>44 1534 517500</personPhoneNum>
          <personAddress>
            <com:street1>19-21</com:street1>
            <com:street2>Broad Street</com:street2>
            <com:city>St Helier</com:city>
            <com:stateOrCountry>Y9</com:stateOrCountry>
            <com:zipCode>JE2 3RR</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001846370</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Richard Griffiths</reportingPersonName>
        <fundType>PF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>Y9</citizenshipOrOrganization>
        <soleVotingPower>14391498.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>14391498.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>14391498.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>7.97</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>* Consists of (i) 10,777,044 ordinary shares represented by American Depositary Shares ("ADSs") held by Ora Capital Limited; (ii) 600,000 ordinary shares represented by ADSs held by Cream Capital Limited; and (iii) 3,014,454 ordinary shares represented by ADSs held by Mr. Griffiths. Each ADS represents, and at the holder's option is convertible into, three ordinary shares of the Issuer. Mr. Griffiths is a director and the controlling shareholder of both Ora Capital Limited and Cream Capital Limited and possesses the power to direct the voting and disposition of these shares.

**This percentage is calculated based upon the 180,628,068 outstanding ordinary shares of the Issuer, as disclosed in the Issuer's last SEC filing.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Ordinary Shares, nominal value of PS0.05 per share</securityTitle>
        <issuerName>Silence Therapeutics Plc</issuerName>
        <issuerPrincipalAddress>
          <com:street1>72 Hammersmith Road</com:street1>
          <com:city>London</com:city>
          <com:stateOrCountry>X0</com:stateOrCountry>
          <com:zipCode>W14 8TH</com:zipCode>
        </issuerPrincipalAddress>
        <commentText>This Amendment No. 11 to Schedule 13D (this "Amendment"), which amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on June 15, 2022, as amended on July 20, 2022, October 20, 2022, August 14, 2023, March 27, 2024, December 18, 2024, March 31, 2025, April 24, 2025, May 8, 2025, June 25, 2025 and 6 July 2026 (the "Schedule 13D") on behalf of Richard Ian Griffiths, relates to the ordinary shares, nominal value PS0.05 per share (the "Shares"), of Silence Therapeutics plc (the "Issuer"). This Amendment is being filed to reflect significant dilution as a result of an increase in the share capital of the Issuer together with open market transactions of the Issuer's ADSs by the Reporting Person. Except as amended and supplemented hereby, the Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Schedule 13D.</commentText>
      </item1>
      <item2>
        <filingPersonName>Richard Griffiths</filingPersonName>
        <principalBusinessAddress>19-21 Broad Street, St Helier, Jersey, JE2 3RR</principalBusinessAddress>
        <hasBeenConvicted>n/a</hasBeenConvicted>
        <convictionDescription>n/a</convictionDescription>
        <citizenship>Jersey, Channel Islands</citizenship>
      </item2>
      <item3>
        <fundsSource>Mr. Griffiths sold an aggregate of 5,484,320 ADSs in open market transactions between August 10, 2026 and August 12, 2026 for aggregate sales proceeds of $87.7M.</fundsSource>
      </item3>
      <item6>
        <contractDescription>n/a</contractDescription>
      </item6>
      <item7>
        <filedExhibits>Schedule 1 Transactions in ADSs During the Past Sixty Days</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Richard Griffiths</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Richard Ian Griffiths</signature>
          <title>Director</title>
          <date>08/13/2026</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>

</edgarSubmission>
